Octapharma Annual Reports provide a comprehensive overview of Octapharma, explaining who we are and what we do. Download the annual reports in English, French, German and Spanish.
In 2023, Octapharma celebrates 40 years of remarkable innovation and growth which has helped transform the lives of countless patients. What started in 1983 as two men with a shared vision to provide haemophilia patients with a safe and efficacious factor VIII (FVIII), has grown into a global company with more than 11,000 employees helping tens of thousands of patients every year live fuller, healthier lives.
In the 2022 Annual Report, we look back on the early origins of our company and explore the role Octapharma played in the development and introduction of the solvent/detergent (S/D) method for the inactivation of enveloped viruses. This technology played a crucial role in the war against viruses such as hepatitis and HIV, and it remains the gold standard for our industry today.
Inside the report, we speak to some of the patients whose lives are being impacted by our products. Suzanne and Eva share their inspiring stories of living with and overcoming debilitating conditions, while Dr Victor Viersen provides his insights based on case studies into how lyophilised plasma can help stabilise and save the lives of trauma patients in a pre-hospital emergency setting.
“In 2023, Octapharma celebrates 40 years of remarkable innovation and growth which has helped transform the lives of countless patients.”
"These strong results came against the backdrop of soaring inflation and continuing supply chain disruptions resulting from the war in Ukraine and the increase in global trade in the aftermath of COVID restrictions."
Download the Octapharma Annual Reports in English, French, German and Spanish, which also contain our complete audited financial statements.
